July 22, 2015
2 min read
Save

Low baseline corneal hysteresis associated with reduced IOP after cataract surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients without glaucoma who underwent cataract surgery with a low baseline corneal hysteresis had decreased postoperative intraocular pressure, according to a study published in the Journal of Cataract & Refractive Surgery.

Perspective from Derek MacDonald, OD, FAAO

“Although using a nonglaucomatous sample limits the applications of this study, we believe that it allowed us to show proof of the concept that [corneal hysteresis] CH is associated with IOP reduction from cataract extraction,” Madhvi Deol, BS, and colleagues wrote in their study. “The present study further shows the potential uses of CH in clinical and research settings.”

Deol and colleagues reviewed the charts of 39 patients (65 eyes) who were a mean of 70.8 years old and underwent phacoemulsification cataract extraction with posterior chamber intraocular lens implantation, according to the study. Patients were measured at 2 months to 4 months postoperatively and 10 months to 12 months postoperatively using the Ocular Response Analyzer (Reichert Inc., Buffalo, N.Y.).

They found that the mean values for IOP were 14.8 ± 3.5 mm Hg at baseline, 11.9 ± 3.4 mm Hg at 2-month to 4-month follow-up, and 12.6 ± 3.1 mm Hg at 12-month follow-up. After controlling for patient age, the baseline CH was significantly associated with the magnitude of IOP reduction at 10 months to 12 months, but not 2 months to 4 months, the authors said.

“We believe that the present study suggests that an understanding of the cornea’s biomechanics might aid clinicians in understanding which patients may or may not have an IOP reduction after cataract extraction,” they concluded. – by Jeffrey Craven

Disclosure: Radcliffe is a consultant for Reichert Technologies, Glaukos, Allergan, Alcon, Iridex, Merge Healthcare and Carl Zeiss Meditec AG, and is a speaker for Merck Pharmaceuticals.